Latest News | Cipla Launches Prostate Cancer-treating Injection

New Delhi, Nov 29 (PTI) Drug firm Cipla on Tuesday said it has launched Leuprolide Acetate Injection Depot 22.5 mg, used in the treatment of prostate cancer.

The product was earlier approved by the US Food and Drug Administration based on a New Drug Application (NDA) regulatory pathway.

Also Read | Drunk Driving Curbs: Delhi Police Asks Uber To Verify Drivers Before Onboarding Them, Check Alcohol Level Before Ride.

"The launch of Leuprolide Acetate Injection Depot reinforces our commitment as an organisation to bring high quality and affordable treatments to patients in the US," Cipla North America CEO Arunesh Verma said in a statement.

The launch of the product aligns with the company's strategy for growth in the complex product segment, he added.

Also Read | TNEB Aadhaar Linking Online: Step-by-Step Guide on How To Link Aadhaar Card with TANGEDCO E-Bill at nsc.tnebltd.gov.in To Get Power Subsidy in Tamil Nadu.

The active ingredient, route of administration, dosage form and strength of the medication are the same as Abbvie's Lupron Depot.

According to IQVIA, Lupron Depot (22.5 mg) had US sales of around USD 197 million for the 12-month period ending September 2022.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)